drugset / Trial / NCT02087241
Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of this study is to combine AZD1775 with standard front-line chemotherapy in subjects with advanced NSCLC.
Timeline
- Start
- 2014-03
- Primary completion
- 2015-06
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adavosertib | Small molecule | 225 mg | Oral |
| Background | Carboplatin | Small molecule | — | — |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |
Indications
No indication recorded.